291.4 ๐Ÿ“‹ ็ซ ๆœซ้€Ÿ่จ˜ Summary

291.4.1 ๐Ÿ”‘ ไธ€ๅฅ่ฉฑ็ธฝ็ต

ๅฆŠๅจ  CV ็”Ÿ็† โ†’ ่ก€้‡ โ†‘ 40-50%ใ€CO โ†‘ 30-50%ใ€SVR โ†“ 20%ใ€HR โ†‘ 10-20๏ผŒpeak stress 28-32 ้€ฑ + L&D + ็”ขๅพŒ 2 ้€ฑ๏ผ›risk stratification mWHO 1-4๏ผˆ4 = ็ฆๆ‡ทๅญ•๏ผšEisenmengerใ€severe PAHใ€severe ASใ€single ventใ€Marfan aorta > 45 mmใ€EF < 30%ใ€severe MS๏ผ‰๏ผ›ๅฆŠๅจ ๆœŸ้‡ๅคง CV ็–พ็—…๏ผšpreeclampsia/eclampsia๏ผˆmagnesium + ๆŽงๅฃ“ + delivery๏ผ‰ใ€peripartum cardiomyopathy (PPCM, HF in last month-5 mo postpartum)ใ€aortic dissection๏ผˆMarfan + 3rd trimester/postpartum ้ซ˜็™ผ๏ผ‰ใ€SCAD๏ผˆperipartum, conservative management๏ผ‰๏ผ›็”จ่—ฅๅฎ‰ๅ…จ: labetalol/methyldopa/nifedipine/hydralazine/digoxin/LMWH/ไฝŽๅŠ‘้‡ ASA ๅฎ‰ๅ…จ๏ผ›็ฆๅฟŒ: ACEi/ARB/MRA/warfarin 1st trimester/DOAC/atenolol/amiodarone/statins/ETAsใ€‚

291.4.2 ๐Ÿ’Š ๆฒป็™‚็ฒพ่ฆ

  • HTN/preeclampsia๏ผšlabetalol๏ผˆIV/PO๏ผ‰ใ€nifedipine ERใ€methyldopaใ€hydralazine๏ผ›severe โ†’ IV labetalol + magnesium sulfate
  • PPCM๏ผšๆจ™ๆบ– HF therapy ๆ”น่‰ฏ็‰ˆ๏ผˆloop + carvedilol/metoprolol + hydralazine/ISDN + LMWH if EF < 35%๏ผ‰๏ผ›bromocriptine ๅฏ้ธ๏ผ›postpartum ๆ”น ACEi/ARB
  • Mechanical valve๏ผšLMWH 1st trimester + warfarin 2nd-3rd + UFH/LMWH peripartum
  • VTE / PE๏ผšLMWH ร— 6 wk postpartum minimum
  • Arrhythmia๏ผšvagal + adenosine (SVT)ใ€metoprololใ€digoxin๏ผ›้ฟๅ… amiodarone

291.4.3 ๐ŸŽฏ ็›ง้†ซๅธซ็š„่€ƒๅ‰ๆ้†’

  1. Peak hemodynamic stress = 28-32 wk + L&D + ็”ขๅพŒ 2 ้€ฑ๏ผˆ้ซ˜ๆญปไบก้ขจ้šชๆ™‚ๆฎต๏ผ‰
  2. mWHO IV ็ต•ๅฐ้ฟๅญ•๏ผšEisenmengerใ€severe PAHใ€severe AS๏ผˆsymptomatic or not๏ผ‰ใ€single ventใ€Marfan > 45 mmใ€BAV > 50 mmใ€EF < 30%ใ€severe MSใ€prior PPCM with ไธๅฏ้€† LV dysfunction
  3. PPCM ็‰นๅพต๏ผšlate pregnancy-5 mo postpartum + LVEF < 45% + ๆŽ’้™คๅ…ถไป–ๅŽŸๅ› ๏ผ›African American 4-10x โ†‘๏ผ›bromocriptine controversial๏ผ›recurrence rate 30-80%
  4. preeclampsia๏ผšBP โ‰ฅ 140/90 + proteinuria/end-organ damage after 20 wk๏ผ›magnesium sulfate for seizure prophylaxis๏ผ›delivery ๆ‰ๆ˜ฏ definitive treatment
  5. aspirin 81-150 mg/d from 12-16 wk ็”จๆ–ผ high-risk preeclampsia ้ ้˜ฒ๏ผˆASPRE 2017๏ผ‰
  6. mechanical valve anticoag๏ผš1st trim LMWH๏ผˆwarfarin embryopathy 5-25%๏ผ‰โ†’ 2nd-3rd trim warfarin๏ผˆๅฆ‚ๅŠ‘้‡ โ‰ค 5 mg/d ้ขจ้šช่ผƒไฝŽ๏ผ‰โ†’ ็”ขๆœŸ UFH/LMWH
  7. pregnancy SCAD๏ผš1-4% of pregnancy MI๏ผ›conservative > PCI๏ผˆhigh re-dissection rate๏ผ‰๏ผ›avoid stress testing in recovery
  8. ็ต•ๅฐ็ฆๅฟŒ่—ฅ๏ผšACEi/ARB/MRA/aliskirenใ€warfarin 1st trimesterใ€DOACsใ€atenolol๏ผˆIUGR๏ผ‰ใ€amiodaroneใ€ETAs๏ผˆteratogenic๏ผ‰ใ€riociguatใ€sotatercept
  9. ๅฎ‰ๅ…จ่—ฅ๏ผšlabetalol๏ผˆfirst-line HTN๏ผ‰ใ€methyldopaใ€nifedipine ERใ€hydralazineใ€digoxinใ€adenosineใ€LMWHใ€low-dose ASA
  10. Marfan + ไธปๅ‹•่„ˆ > 4.5 mm๏ผšpre-pregnancy ไฟฎ่ฃœ๏ผ›ไธไฟฎ่ฃœ็š„่ฉฑ่€ƒๆ…ฎ cesarean delivery + ฮฒ-blocker continuation